Cipla has launched what it claims is the first biosimilar version of etanercept in India, under the brand name Etacept. The product, used in the treatment of rheumatic disorders, is a biosimilar version of Pfizer/Amgen's Enbrel. Cipla's etanercept is manufactured by Shanghai CP Guojian Pharmaceutical, as part of a manufacturing alliance between the two firms.
Shanghai CP Guojian Pharmaceutical first launched its etanercept in China in 2006. In India, Etacept will be available as a lyophilised powder to be given by subcutaneous injection; the recommended dose for adults is 25mg twice weekly. Cipla commented that the version is available with stockists across India at Rs 6,150, and noted that this was around 30 per cent lower than the innovator version.